TRAW vs AVIR

Analysts rate Atea Pharmaceuticals, Inc.

(AVIR) a "Hold" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Atea Pharmaceuticals, Inc.

(AVIR) delivered a total return of -74. 0%, compared to -99. 2% for Traws Pharma, Inc. (TRAW). Over 10 years, the gap is even starker: AVIR returned -81. 7% versus TRAW's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atea Pharmaceuticals, Inc.

(AVIR) is the lower-risk stock at 1. 05β versus Traws Pharma, Inc. 's 1. 60β — meaning TRAW is approximately 52% more volatile than AVIR relative to the S&P 500.

On earnings-per-share growth, the picture is similar: Atea Pharmaceuticals, Inc.

grew EPS 3. 0% year-over-year, compared to -56. 0% for Traws Pharma, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Atea Pharmaceuticals, Inc.

(AVIR) is the more profitable company, earning 0. 0% net margin versus -241. 9% for Traws Pharma, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AVIR leads at 0. 0% versus -218. 4% for TRAW. At the gross margin level — before operating expenses — TRAW leads at 94. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Atea Pharmaceuticals, Inc.

(AVIR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05)). Traws Pharma, Inc. (TRAW) carries a higher beta of 1. 60 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AVIR: -81. 7%, TRAW: -100. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.